Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain  by Manzur, A. et al.
RESEARCH NOTE
Community-acquired methicillin-resistant
Staphylococcus aureus infections: an
emerging threat in Spain
A. Manzur1, A. M. Dominguez2, M. Pujol1,
M. P. M. Gonza´lez2, E. Limon1, A. Hornero1,
R. Martı´n2, F. Gudiol1 and J. Ariza1
1Infectious Diseases Service and 2Microbiology
Service, Hospital Universitari de Bellvitge,
L’Hospitalet Llobregat, Barcelona, Spain
ABSTRACT
Community-acquired methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) has not been recogni-
sed previously as a cause of MRSA infections in
Spain. Nineteen patients carrying Panton–Valen-
tine leukocidin (PVL)-positive MRSA were iden-
tiﬁed in a Barcelona hospital, of whom 15 were
immigrants, mostly from South America. Twelve
developed skin and soft-tissue infections. The
associated isolates carried the PVL gene and
staphylococcal chromosomal cassette (SCC)mecIV.
A dominant clone belonging to sequence type
(ST)8 and related to the USA300 clone was
identiﬁed by pulsed-ﬁeld gel electrophoresis. This
clone is emerging in Spain, primarily among
immigrants from South America, but dissemina-
tion to the native Spanish population could
increase.
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Methicillin-resistant Staphylococcus aureus (MRSA)
has emerged as a cause of community-acquired
(CA) infections. Transmission from person to
person has been well-documented and ascribed
to close contact [1]. In the USA, MRSA is the most
frequent cause of staphylococcal skin and soft-
tissue infections (SSTIs) [2], and is associated with
a predominant clone, USA300 [3], which belongs
to multilocus sequence type (ST)8, carries staphy-
lococcal cassette chromosome (SCC)mecIV, and
produces Panton–Valentine leukocidin (PVL).
Typically, CA-MRSA is susceptible to most anti-
staphylococcal agents, although antibiotic resis-
tance is increasing [4,5].
The prevalence of CA-MRSA varies across
Europe [6–8], but in Spain, which has high
endemic rates of hospital-acquired MRSA
(HA-MRSA) [9], there has only been a single
report of CA-MRSA infection [10]. However, an
increase in PVL-positive MRSA infections in
Barcelona was observed recently. The present
study aimed to determine the frequency of
PVL-positive strains among MRSA isolates from
Hospital Universitari Bellvitge (HUB), and to
establish their characteristics, genetic traits and
clinical manifestations.
HUB is a 900-bed tertiary-care teaching hospital
in Barcelona, Spain. In 2006, 13% of the regional
population of 7 million were immigrants, with
10% originating from Ecuador. The MRSA infec-
tion control programme includes active surveil-
lance of patients at high risk of MRSA carriage,
together with isolation and follow-up of all
MRSA-positive patients detected by screening or
clinical samples. Patients with PVL-positive
MRSA were identiﬁed using microbiology reports
and were visited by an infectious disease special-
ist. Community acquisition was considered when
patients had no known previous contact with the
healthcare system.
In 2003, a PVL-positive MRSA strain was
isolated from a cutaneous abscess. A retrospective
search for PVL-positive MRSA was then con-
ducted for the period 2001–2003, followed by a
prospective search during 2004–2007, concentrat-
ing on isolates with an antibiotic resistance proﬁle
(susceptible to erythromycin, clindamycin, tobra-
mycin, and ⁄ or ciproﬂoxacin) which differed from
that of the endemic strains dominant in HUB. In
total, 73 isolates with the above susceptibility
pattern from 1337 patients infected or colonised
with MRSA during the 2001 to June 2007 period
were tested for PVL. In addition, 30 isolates
representative of epidemic HA-MRSA strains
were screened for PVL genes by PCR co-ampli-
ﬁcation of genes encoding the class S (lukS-PV)
and class F (lukF-PV) proteins speciﬁc for PVL
Corresponding author and reprint requests: A. Manzur,
Infectious Diseases Service, Hospital Universitari de Bellvitge,
Feixa Llarga sn., L’Hospitalet Llobregat, E-08907 Barcelona,
Spain
E-mail: admanzur@yahoo.com.ar
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases
[11]. Ampliﬁcation conditions comprised 30 cy-
cles of 94C for 30 s, 55C for 30 s and 72C for
1 min, with a ﬁnal extension at 72C for 4 min.
The expected size of the PCR products was
432 bp. PCR products were detected by electro-
phoresis on agarose 1.5% w ⁄ v gels and ethidium
bromide staining. Antibiotic susceptibility testing
was performed by the disk-diffusion method,
with susceptibility interpreted according to CLSI
criteria [12]. The presence of the mecA gene was
conﬁrmed by PCR [13].
Macrorestriction analysis of chromosomal
DNA was performed for all but one of the PVL-
positive MRSA isolates. SmaI-digested DNA frag-
ments were separated by pulsed-ﬁeld gel electro-
phoresis (PFGE) in a CHEF-DRIII unit (BioRad,
Madrid, Spain), for 23 h at 6 V ⁄ cm and 14C, with
pulses ranging from 1 to 30 s. PFGE patterns were
interpreted according to Tenover et al. [14].
SCCmec elements were identiﬁed by PCR [15].
Multilocus sequence typing [16] was performed
for ﬁve representative isolates belonging to the
predominant clones.
The frequency of methicillin resistance among
S. aureus isolates in the hospital increased from
15% in 2001 to 26% in 2007 (January–June).
Between January 2001 and June 2007, 19 patients
yielded PVL-positive MRSA isolates, representing
1.5% of the total MRSA isolates (n = 1337) during
this period. None of the HA-MRSA isolates
carried PVL genes.
Of the 19 patients carrying PVL-positive
MRSA, 15 were immigrants (Table 1). Dissemi-
nation of strains was observed in three families
(Table 1; patients 9–13, 16–17 and 18–19). Twelve
(63%) patients were females. The median age
was 31 years (range 10–69 years). Six patients
were nasal carriers. Thirteen (68%) patients
developed infections; ten patients had SSTIs
and three other unrelated patients developed
infection >48 h after admission (Table 1; patients
8, 15 and 18).
Isolates from 18 patients (one per patient) were
available for molecular characterisation. Twelve
isolates, including isolates from nine Ecuadorian
patients, belonged to a predominant genotype
(clone A) according to PFGE, and three isolates
belonged to a minor genotype (clone B). Repre-
sentative isolates of clones A and B belonged to
ST8 and ST5, respectively (Fig. 1). Irrespective
of clonal characterisation, all isolates carried
SCCmecIV and were susceptible to most antibiot-
ics (Table 1).
Few MRSA clones in HUB carry the PVL genes;
the isolates in the present study were identiﬁed as
CA-MRSA and did not spread through the hos-
pital. The PVL-positive isolates had diverse
genetic backgrounds, but a predominant clone
(SCCmecIV, ST8) was identiﬁed. PVL-positive
MRSA strains of ST8 belong to a clone (USA300)
that is spread widely in the USA. Remarkably, the
ST80 clone, which is common in Europe [17], was
Table 1. Characteristics of patients yielding community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)
and microbiological characterisation of the CA-MRSA isolates
Patient Gender Age (years) Country of origin NS Clinical manifestation Treatment RP PVL PFGE SCCmec ST
1 F 48 Ecuador ND Cutaneous abscesses oxa–tetra + A IV
2 F 36 Ecuador ND Cutaneous abscesses Drainage oxa–tetra + A IV
3 F 20 Ecuador ND Cutaneous abscesses oxa–tetra + A IV ST8
4 F 31 France ND Cutaneous abscesses TMP–SMX oxa + C IV
5 F 31 Spain ND Cutaneous abscesses Drainage–A ⁄C oxa + D IV
6 F 69 Spain + None oxa + A IV
7 F 62 Ecuador + None oxa + A IV
8 M 29 Rumania + Surgical site infection Drainage–CLIND oxa–tetra–fus + E IV
9 F 39 Ecuador + None oxa + A IV
10 M 43 Ecuador + Cutaneous abscesses CLIND oxa + A IV ST8
11 F 44 Ecuador + Cutaneous abscesses CLIND oxa + A IV
12 M 21 Ecuador + None oxa + A IV
13 M 10 Ecuador + None oxa + A IV
14 M 29 Colombia ) Cutaneous abscess Drainage–CLIND oxa–tetra + A IV
15 F 40 Spain + Decubitus ulcer infection Drainage oxa–tetra + A IV
16 M 29 Spain + Septic bursitis Drainage–CLIND oxa + B IV ST5
17 F 28 Spain + Cutaneous abscesses CLIND oxa + ND ND
18 M 45 Peru + Tracheobronchitis CLIND oxa + B IV ST5
19 F 34 Peru + None oxa + B IV ST5
M, male; F, female; NS, nasal swab; RP, resistance proﬁle; ND, not done; oxa, oxacillin; tetra, tetracycline; fus, fusidic acid; TMP–SMX, trimethoprim–sulphamethoxazole; A ⁄C,
amoxycillin plus clavulanate; CLIND, clindamycin; ST, sequence type; PVL, Panton–Valentine leukocidin; PFGE, pulsed-ﬁeld gel electrophoresis; SCC, staphylococcal
chromosomal cassette.
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not found among the present set of isolates. In
Spain, the only previous report of CA-MRSA
infection concerned the paediatric population of
Madrid, with most patients belonging to Ecuado-
rian families [10]. Together with the present
results, this suggests that a clone related to
USA300 is spreading among the local population,
and particularly among Ecuadorian immigrants.
The geographical distribution of this clone (lim-
ited to the USA before 2003) has expanded to
Europe [18], but this can usually be linked to
American travellers [18,19]. In the present study,
this clone may have been imported from South
America.
Although evidence suggests that CA-MRSA is
increasing in South America [20–22], no data are
available for Ecuador. USA300 has not been
reported to be an epidemic clone in this region.
Clonal dissemination in immigrant populations
probably precedes wider dissemination through-
out an entire community. A high rate of nasal
carriage and dissemination from patients to rela-
tives was observed in the present study. Thus,
screening and decontamination (using mupirocin)
of close contacts of patients infected or colonised
with PVL-positive MRSA should be considered
[6,7]. The CA-MRSA infections observed were
similar to those described previously [3]; remark-
ably, three patients developed nosocomial infec-
tions following colonisation with an endogenous
PVL-positive MRSA strain. This situation requires
the implementation of strict precautionary mea-
sures to avoid the spread of new MRSA clones
within the hospital.
The recognition of CA-MRSA has implications
for both antimicrobial treatment and MRSA sur-
veillance. Although such strains are susceptible to
most anti-staphylococcal agents, resistance to
clindamycin is increasing [4,5]. Close surveillance
is essential to monitor the introduction of
CA-MRSA into hospitals, as well as changes in
resistance proﬁles and disease associations [22].
The epidemiological data suggest that a predom-
inant CA-MRSA clone has emerged in Spain as a
cause of SSTIs affecting family groups, mainly
immigrants from South America. Spain has
recently experienced a wave of immigration,
mainly from South America. The ST8 clone can
be linked to this migratory ﬂow, although dis-
semination among the native Spanish population
could now increase.
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Fig. 1. Pulsed-ﬁeld gel electrophoresis (PFGE) patterns of 15 Panton–Valentine leukocidin-positive methicillin-resistant
Staphylococcus aureus isolates.
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